Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „across“
Suchtreffer
Begriffe & Kennungen
Aybintio · 4.8 · Across all clinical trials, mucocutaneous haemorrhage has been seen in up to 50% of bevacizumab-treated patien
Eintrag öffnenAybintio · 4.8 · Across clinical trials, the following Grade 3 and 4 (NCI-CTCAE v.3) laboratory abnormalities occurred in patie
Eintrag öffnenAybintio · 4.8 · Haemorrhage (see section 4.4) In clinical trials across all indications the overall incidence of NCI-CTCAE v.3
Eintrag öffnenAybintio · 4.8 · In clinical trials across indications, the overall incidence of venous thromboembolic reactions ranged from 2.
Eintrag öffnenAybintio · 4.8 · The most frequently observed adverse reactions across clinical trials in patients receiving bevacizumab were h
Eintrag öffnenBenepali · 4.8 · 15 In the double-blind periods of controlled clinical trials of etanercept across all indications, the frequen
Eintrag öffnenBenepali · 4.8 · Autoimmune hepatitis In controlled clinical trials of etanercept across all indications, the frequency (incide
Eintrag öffnenBenepali · 4.8 · Autoimmune hepatitis In controlled clinical trials of etanercept across all indications, the frequency (incide
Eintrag öffnenBenepali · 4.8 · Elevated liver enzymes In the double-blind periods of controlled clinical trials of etanercept across all indi
Eintrag öffnenBenepali · 4.8 · Interstitial lung disease In controlled clinical trials of etanercept across all indications, the frequency (i
Eintrag öffnenBenepali · 4.8 · Interstitial lung disease In controlled clinical trials of etanercept across all indications, the frequency (i
Eintrag öffnenBiktarvy · 4.8 · The assessment of adverse reactions is based on safety data from across all Phase 2 and 3 studies with Biktarv
Eintrag öffnenBimzelx · 4.8 · Across indications, no clinically meaningful impact on clinical response was associated with anti- bimekizumab
Eintrag öffnenBlincyto · 4.8 · The type and frequency of adverse reactions were similar across different paediatric subgroups (gender, age an
Eintrag öffnenBrilique · 4.8 · The bleeding profile of ticagrelor 60 mg was consistent across multiple pre-defined subgroups (e.g. by age, ge
Eintrag öffnenBrilique · 4.8 · The bleeding profile of ticagrelor 60 mg was consistent across multiple pre-defined subgroups (e.g. by age, ge
Eintrag öffnenBrilique · 4.8 · The bleeding profile of ticagrelor 60 mg was consistent across multiple pre-defined subgroups (e.g. by age, ge
Eintrag öffnenCabazitaxel Accord · 4.8 · Discontinuation of treatment due to adverse reactions occurred with similar frequencies across the 3 studies (
Eintrag öffnenCinryze · 4.8 · Across clinical studies, there were 61 unique paediatric subjects enrolled and exposed to over 2 500 infusions
Eintrag öffnenColobreathe · 4.8 · In the 24 week clinical study, the following adverse reactions were observed across all ages. Frequencies are
Eintrag öffnen